Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "Methylphenidate Hydrochloride (CAS 298-59-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel ...

Extended-Release Is Now Chewable: First and Only Long-Acting Chewable Methylphenidate Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 6 years old and above Monday, ...

Methylphenidate hydrochloride extended-release tablets should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and ...

STAMFORD, Conn.--(BUSINESS WIRE)--Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application ...

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg ...

The Food and Drug Administration (FDA) has expressed concerns about the therapeutic equivalence of two generic versions of Concerta (methylphenidate HCl extended-release; Janssen) tablets indicated ...

Medication offers relief from 'home to homework' 25 FEBRUARY 2002 – London, UK -- A new, once-daily treatment for attention deficit hyperactivity disorder (ADHD), Concerta® XL (methylphenidate HCl), ...

Methylphenidate HCl 10mg, 20mg, 30mg, 40mg; ext-rel caps (one-half as immediate-release + one-half as enteric-coated, delayed-release beads). Not recommended in pediatric patients <6yrs due to a ...

To compare efficacy of cognitive behavioral group psychotherapy with individual clinical management and methylphenidate hydrochloride with placebo, researchers conducted a prospective, multicenter ...